InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Anand Bhaskar, Vice-Président, Responsable de la Comptabilité. Director active across 2 companies, notably Reata Pharmaceuticals INC. Aggregated, 12 filings have been logged. Split: 0 buy · 5 sells. Total volume traded: €250k. Activity tracked since 3 January 2022. The latest transaction was disclosed on 21 October 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Anand Bhaskar
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
26,680 shares@ US$18.7448.7% of flowCommon StockSEC:0001890784-25-000005:0
22,026 shares@ US$22.70100.0% of flowCommon StockSEC:0001599298-24-000135:0
24,089 sharesClass A common stockSEC:0000899243-23-019532:0
406 shares@ US$169.2022.1% of flowClass A common stockSEC:0001209191-23-048601:0
193 shares@ US$169.05510.3% of flowClass A common stockSEC:0001209191-23-046276:0
1,562 shares@ US$27.3213.6% of flowClass A common stockSEC:0001209191-23-037802:0
950 shares@ US$85.983326.0% of flowClass A common stockSEC:0001209191-23-030181:0
165 shares@ US$84.584.5% of flowClass A common stockSEC:0001209191-23-017248:0
820 shares@ US$87.4723.4% of flowClass A common stockSEC:0001209191-23-016281:0
3,000 shares0Class A common stockSEC:0001209191-23-014817:0
8,250 shares0Class A common stockSEC:0001209191-23-000851:0
12,500 shares0Class A common stockSEC:0001209191-22-001640:0
12 of 12 declarations
About Anand Bhaskar
Bhaskar Anand is Vice President and Chief Accounting Officer at REATA PHARMACEUTICALS INC. In this role, he oversees the company's accounting and financial operations, ensuring the accuracy of financial reporting. REATA PHARMACEUTICALS INC. is a biopharmaceutical company focused on developing innovative treatments.
